Plx Pharma Stock Story

PLXP -  USA Stock  

USD 2.36  0.05  2.16%

Merck Kgaa would recover faster from the current slide as its shares price went up 0.71% to Plx Pharma's 7.53%While some millenniums may be indifferent towards healthcare space, we will examine how healthy are Plx Pharma fundamentals compared to Merck Kgaa. We are going to focus on some of the competitive aspects of both Plx Pharma and Merck.
Published over three months ago
View all stories for Plx Pharma | View All Stories
Should we be obtaining Merck or Plx Pharma?
By analyzing existing basic indicators between Plx Pharma and Merck, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in Merck with a short position in Plx Pharma. Check out our pair correlation module for more information.

Let's begin by analyzing the assets.
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Plx Pharma has an asset utilization ratio of 42.69 percent. This suggests that the company is making $0.43 for each dollar of assets. An increasing asset utilization means that Plx Pharma is more efficient with each dollar of assets it utilizes for everyday operations.

How important is Plx Pharma's Liquidity

Plx Pharma financial leverage refers to using borrowed capital as a funding source to finance Plx Pharma ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Plx Pharma financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Plx Pharma's total debt and its cash.

How does Plx Pharma utilize its cash?

To perform a cash flow analysis of Plx Pharma, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Plx Pharma is receiving and how much cash it distributes out in a given period. The Plx Pharma cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.


Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Revenue Breakdown

Let me now analyze Plx Pharma revenue. Based on the latest financial disclosure, Plx Pharma reported 6.62 M of revenue. This is 99.91% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The revenue for all United States stocks is 99.93% higher than that of the firm. As for Merck Kgaa we see revenue of 19.07 B, which is much higher than that of the Drug Manufacturers—Specialty & Generic

19.1 B
PLXP6.62 Million0.0347
MKKGY19.07 Billion99.97

Breaking up Plx Pharma recent price decline

The maximum drawdown is down to 28.14 as of today.
As of the 11th of March 2022, Plx Pharma holds the coefficient of variation of (752.56), and Risk Adjusted Performance of (0.13). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Plx Pharma, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We have analyzed and interpolated nineteen technical drivers for Plx Pharma, which can be compared to its competitors. Please check Plx Pharma standard deviation, as well as the relationship between the value at risk and kurtosis to decide if Plx Pharma is priced some-what accurately, providing market reflects its current price of 4.05 per share. Given that Plx Pharma has jensen alpha of (0.66), we recommend you to check out Plx Pharma's recent market performance to make sure the company can sustain itself at a future point.

Our Conclusion on Plx Pharma

Although few other entities in the drug manufacturers—specialty & generic industry are either recovering or due for a correction, Plx Pharma may not be performing as strong as the other in terms of long-term growth potentials. To conclude, as of the 11th of March 2022, our analysis shows that Plx Pharma almost mirrors the market. The firm is undervalued and projects above average probability of financial unrest for the next 2 years. However, our present 90 days 'Buy-Sell' recommendation on the firm is Strong Sell.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Plx Pharma. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to